Tracers / [68Ga]DOTA-r-a-ABA-iodoCPCR4
[68Ga]DOTA-r-a-ABA-iodoCPCR4
- Radionuclide
- Ga-68 t½ 67.71 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated CPCR4-based cyclic pentapeptide (CXCR4-targeting ligand)
- Target / mechanism
- CXCR4 receptor PMID 32724470
- Clinical application
- —
- Theranostic pair
- <a href="/tracers/lu177-dotaraabaiodocpcr4/">lu177-dotaraabaiodocpcr4</a>
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 32724470 2020 Theranostics |
| Manual synthesis | — | — | — | — | DOTA-r-a-ABA-iodoCPCR4 | 32724470 2020 Theranostics All peptides and their respective natGa-, natLu-, natY- and natBi- complexes were synthesized in analogy to previously published protocols |
Need this precursor?We can point you to suppliers for [68Ga]DOTA-r-a-ABA-iodoCPCR4, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 32724470. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 32724470: 'DOTA-r-a-ABA-iodoCPCR4 (entry 14)'. Stage set/updated at stage 23 from PMID 32724470: 'will be further evaluated in preclinical and clinical CXCR4-targeted dosimetry and RLT studies.'.